Arax Advisory Partners’s BioCryst Pharmaceuticals BCRX Stock Holding History

Arax Advisory Partners’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$203K	Buy	20,286 +19,781	+3,917%	+$179K	﹤0.01%	2241
2026 Q1	$4.53K	Buy	505 +459	+998%	+$3.56K	﹤0.01%	2826
2025 Q4	$359	Sell	46 -2,947	-98%	-$21.3K	﹤0.01%	3650
2025 Q3	$22.7K	Buy	2,993 +2,290	+326%	+$19.1K	﹤0.01%	2204
2025 Q2	$6.3K	Sell	703 -408	-37%	-$3.8K	﹤0.01%	2152
2025 Q1	$8.33K	Buy	1,111 +373	+51%	+$3.01K	﹤0.01%	1619
2024 Q4	$5.55K	Hold	738	–	–	﹤0.01%	1706
2024 Q3	$5.61K	Sell	738 -40	-5%	-$304	﹤0.01%	1667
2024 Q2	$4.81K	Buy	778 +694	+826%	+$3.83K	﹤0.01%	1614
2024 Q1	$426	Buy	84 +32	+62%	+$180	﹤0.01%	1244
2023 Q4	$312	Hold	52	–	–	﹤0.01%	1255
2023 Q3	$368	Hold	52	–	–	﹤0.01%	1260
2023 Q2	$367	Buy	52 +1	+2%	+$8	﹤0.01%	1225
2023 Q1	$426	Buy	51 +13	+34%	+$125	﹤0.01%	1212
2022 Q4	$436	Buy	+38	New	+$474	﹤0.01%	1194

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

Jupiter Topco New York $245B AUM

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Arax Advisory Partners's BCRX Position: Q2 2026 in Review

Arax Advisory Partners increased its BioCryst Pharmaceuticals (BCRX) stake by 3,917% in Q2 2026, buying an estimated $179K and bringing the position to 20,286 shares worth $203K. The position accounts for ﹤0.01% of the portfolio, ranked #2241.

Arax Advisory Partners first reported a position in BCRX in Q4 2022 and has held it in 15 quarters since. 318 funds tracked by Wall St. Rank hold BCRX as of Q2 2026.

Arax Advisory Partners held 20,286 shares of BioCryst Pharmaceuticals worth $203K as of Q2 2026.
Arax Advisory Partners bought 19,781 BioCryst Pharmaceuticals shares in Q2 2026, an estimated $179K.
BioCryst Pharmaceuticals made up ﹤0.01% of Arax Advisory Partners's portfolio in Q2 2026, its #2241 holding.
Arax Advisory Partners first reported a position in BioCryst Pharmaceuticals in Q4 2022 and has held it in 15 quarters since.
318 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q2 2026.

Based on Arax Advisory Partners's 13F filing for Q2 2026, filed 10 Aug 2026.